

1 **Enhanced surveillance of monkeypox in Bas-Uélé, Democratic Republic of Congo: the**
2 **limitations of symptom-based case definitions**

3 Gaspard Mande^a Innocent Akonda^b, Anja De Weggheleire^c, Isabel Brosius^c, Laurens
4 Liesenborghs^c, Emmanuel Bottieau^c, Noam Ross^d, Guy -Crispin Gembu^e, Robert Colebunders^f,
5 Erik Verheyen^{g,h}, Ngonda Dauly^a, Herwig Leirs^h, Anne Laudisoit^{d,h*}

6 ^aUniversity of Kisangani (UNIKIS), Faculty of Medicine and Pharmacy, BP 2012, Kisangani,
7 Democratic Republic of Congo

8 ^bMinistry of Health, Buta, Democratic Republic of Congo

9 ^cOutbreak research team, Department of Clinical Sciences, Institute of Tropical Medicine (ITM),
10 Nationalestraat 155, 2000 Antwerp, Belgium

11 ^dEcohealth Alliance, 520 8th Avenue, 10018 New York, NY, United States of America

12 ^eUniversity of Kisangani (UNIKIS), Faculty of Science and Center for Biodiversity monitoring
13 (CSB), BP2012, Kisangani, Democratic Republic of Congo

14 ^fGlobal Health Institute, University of Antwerp, Campus drie Eiken, Gouverneur Kinsbergen
15 Centrum, Doornstraat 331, 2610 Wilrijk, Belgium

16 ^gRoyal Belgian Institute of Natural Sciences, Rue Vautier 29, 1000 Brussels, Belgium

17 ^hEvolutionary Ecology Group (EVECO), University of Antwerp, Campus Drie Eiken
18 Universiteitsplein 1, 2610 Wilrijk, Belgium

19

20 *Correspondence: Anne Laudisoit, +1-917-912-2155, laudisoit@ecohealthalliance.org

21

22

23

24 **Abstract**

25 *Background:* Following an outbreak of cases of vesicular-pustular rash with fever evocative of
26 human monkeypox in Bas-Uélé province, Democratic Republic of Congo, surveillance was
27 strengthened.

28 *Methods:* Households with at least one active generalized vesicular-pustular rash case were
29 visited, and contact and clinical history information was collected from all household members.
30 Whenever possible, skin lesion were screened by PCR for the monkeypox virus, followed by the
31 varicella-zoster virus when negative for the former.

32 *Results:* PCR results were obtained for 77 suspect cases distributed in 138 households, of which
33 27.3% were positive for monkeypox, 58.4% for chickenpox, and 14.3% negative for both.

34 Confirmed monkeypox cases presented more often with monomorphic skin lesions, on palms of
35 hands, and on soles of feet. Integrating these three features into the case definition raised the
36 specificity to 85%, but would miss 50% of true monkeypox cases. A predictive model fit on
37 patient demographics and symptoms had 97% specificity and 80% sensitivity, but only 80% and
38 33% in predicting out-of-sample cases.

39 *Conclusion:* Few discriminating features were identified and the performance of clinical case
40 definitions was suboptimal. Rapid field diagnostics are needed to optimize worldwide early
41 detection and surveillance of monkeypox.

42

43 **Keywords:** monkeypox; Democratic Republic of Congo; chickenpox, diagnostic, Orthopoxvirus

44

45

46

47

48

49 **Background**

50 Monkeypox virus (MPXV) is a DNA virus belonging to the Poxviridae family, which includes
51 vaccinia, cowpox and variola (smallpox) viruses. MPXV is currently the most prevalent human
52 Orthopoxvirus and has been re-emerging since the eradication of smallpox in 1980. In humans, it
53 causes a disease similar to smallpox, called monkeypox (Durski et al., 2018). Two clades of
54 MPXV have been identified: the West African clade (MPXV-WA) occurring in forest areas
55 situated west of Nigeria, and the Congo Basin clade (MPXV-CB) in Central Africa (Sklenovská
56 and Van Ranst, 2018). After an incubation period of usually 7 to 14 days (range from 5 to 21
57 days), human monkeypox typically begins with systemic symptoms (i.e. fever, myalgia)
58 followed by a rash, starting on the face before centrifugally spreading to other parts, including
59 hands and feet. The skin lesions generally appear all at the same stage (monomorphic), evolving
60 within 2 to 4 weeks from macules to papules, vesicles, pustules, crusts, and scabs. Complications
61 are frequent and mortality may be up to 10% in children. People (primary cases) get infected
62 through contact with infected animals during farming, hunting, or bushmeat preparation
63 activities, and human-to-human transmission (secondary cases) also occurs by respiratory
64 droplets or by close contact with infected lesions or bodily fluids (Diaz, 2021, Makhani et al.,
65 2019, Petersen et al., 2019).

66 Human monkeypox was first described in 1970 in the Democratic Republic of the Congo (DRC)
67 (Ladnyj et al., 1972). It is now found in more than half of the health zones of the country,
68 reaching an incidence exceeding 5000 cases per year. More than 35 epidemics have been
69 reported in other African countries and in recent years cases have also been increasing in
70 returning travelers (Erez et al., 2019, Hobson et al., 2021, Mauldin et al., 2020, Rao et al., 2022,
71 Yong et al., 2020) culminating in 2022 in an unprecedented multi-country outbreak (WHO,
72 2022). Since 2002, monkeypox is a notifiable disease in DRC and part of the nationwide

73 implemented Integrated Disease Surveillance and Response (IDSR) system (DRC, 2011, 2012).
74 All suspected clinical cases (and deaths) that meet the clinical case definition have to be reported
75 weekly by each health zone to the national level (Hoff et al., 2017). As shown in Table 1, two
76 case definitions of “suspect monkeypox cases” are provided in the national IDSR guideline: one
77 for use in health facilities by nurses/doctors and a second one much broader (“fever and
78 cutaneous rash”) designed for surveillance by community health workers.
79 Due to the remoteness of the endemic areas confirmatory testing by PCR, only available in the
80 national reference laboratory (“Institut National de Recherche Biomédicale”, INRB, Kinshasa),
81 is rarely performed. As a result, the robustness of field surveillance based on clinical suspicion
82 has so far been difficult to evaluate. Several diseases with generalized skin eruption may mimic
83 monkeypox, such as chickenpox, measles, molluscum contagiosum, or rickettsioses. The field
84 differential diagnosis between monkeypox and chickenpox is particularly challenging (Jezek et
85 al., 1988, Leung et al., 2019, MacNeil et al., 2009) and coinfections are frequent (Hughes et al.,
86 2020). Recent attempts to design clinical case definitions with a higher specificity for
87 surveillance or care purposes have not yet undergone external validation (Osadebe et al., 2017).
88 Following alerts from several health zones of the Bas-Uélé province, northeastern DRC (Aketi,
89 Buta, and Titule; Figure 1) of a sharp increase of suspect monkeypox cases a first exploratory
90 mission was conducted in 2016 and confirmed an ongoing outbreak of febrile illness with skin
91 eruption, suspect monkeypox. It also identified important challenges and gaps impacting the
92 quality of the surveillance and outbreak data, including the non-systematic registration of cases
93 and the scarcity of sampling kits in the field. An active surveillance component was added, and
94 access to confirmatory testing was reinforced through the project entitled "Strengthening

95 academic capacity to respond to Monkeypox epidemics: discrimination and origin of eruptive
96 fevers in the Democratic Republic of Congo (DRC)" (Laudisoit, 2017).

97

98 **Methods**

99 *Study design, setting and population*

100 In the framework of the project, enhanced active surveillance and household investigation of
101 suspect monkeypox cases were first initiated in three health zones (Aketi, Buta, Titule) of the
102 Bas-Uélé province, and later focused on the axis going North from Aketi (Figure 1), where most
103 cases had been initially detected. This region is located in the lowland tropical rainforest of the
104 Congo Basin, with a long rainy season from April to November, where the population lives
105 mainly from subsistence farming, hunting, and small-scale livestock breeding.

106 The study population consisted of all suspect monkeypox cases as well as all members of their
107 households, residing in locations accessible to trained study collaborators. For this study, a
108 suspect monkeypox case was defined as "any person with an active generalized vesicular-
109 pustular rash, i.e., presenting with five or more cutaneous lesions such as macules, papules,
110 vesicles, pustules, or crusts, (Table 1)", based on the DRC case definition for community
111 surveillance (DRC, 2012). This study case definition was a bit stricter than that for community
112 surveillance (a minimal number of lesions was required) but still aimed to largely capture any
113 patients with active skin eruption that could be sampled for diagnostic evaluation.

114

115 *Enhanced surveillance and household investigation*

116 Households in which at least one case of febrile eruptive skin disease was reported by
117 community health care workers (RECO) were visited by the study team. The household visits

118 were done during three field sessions (08-21/09/2017, 19-29/03/2018, 27/10-9/11/2018) and
119 during the interval periods by trained registered nurses from the study areas.

120 At the household level, after having obtained written informed consent for household inclusion
121 from the household head, epidemiological and clinical data were collected (number of household
122 members, gender and age of each member, health zone/area and village of residence,
123 geographical coordinates, past episodes of fever with skin eruption and smallpox vaccination
124 status of each household member). In addition, for each individual considered as a suspect
125 monkeypox case, signs and symptoms (focused on monkeypox features such as fever prodrome,
126 type/stage of rash, ocular lesions, cervical lymphadenopathy), and risk factors (contact with sick
127 person, animal contact, type of contact, time since contact) were collected using standardized
128 questionnaires. In case of additional individual consent (or ascent by child plus consent of
129 parent/tutor in case of children) and if sampling material was available, up to a maximum of 2
130 skin biopsies (crusts, pustules, or vesicle liquid) were collected following a strict standard
131 operational procedure. One skin biopsy was stored 'dry' at room temperature in individual vials
132 as per DRC monkeypox case management and surveillance guidelines and sent to INRB in
133 Kinshasa (DRC, 2012). The second biopsy was stored in ethanol (70%) as a back-up and stored
134 at UNIKIS. Venous blood was not collected. Data on outcomes or onward human-to-human
135 transmission were not available, as cases and their households were not followed up
136 longitudinally after the initial visit. During each field visit, information obtained in one
137 household could lead to further investigational visits in other households of the same village
138 (snowball enrolment).

139

140

141 *Laboratory procedures*

142 Skin lesion samples were screened at the virology laboratory of INRB, Kinshasa, for
143 Orthopoxviruses (OPXV) using an Orthopoxvirus-specific real-time in-house PCR assay
144 (Osadebe et al., 2017). If the lesions tested negative for OXPV, a second real-time PCR assay
145 targeting the varicella-zoster virus (VZV) was performed. OPXV positive samples were not
146 tested further for VZV and were considered MPXV as no other circulating human pathogenic
147 Orthopoxvirus causes a similar smallpox-like rash. Results were officially reported back from
148 the reference laboratory (INRB) to the provincial central health bureau as positive, negative, or
149 “neither MPXV nor VZV”, after interpretation of cycle threshold values.

150

151 *Evaluation of clinical case definitions*

152 After this study was designed and approved, another research group published the results of a
153 large case series of confirmed monkeypox and chickenpox cases and evaluated the DRC health
154 facility case definition (called case definition A in this manuscript) and an alternative one (case
155 definition B, elaborated to better discriminate both conditions) (Table 1). In addition, based on a
156 receiver operating characteristic model including a set of 12 signs and symptoms, other
157 combinations were proposed, since the performance of both case definitions A and B was
158 unsatisfactory (Osadebe et al., 2017). We used our dataset retrospectively to also evaluate the
159 diagnostic accuracy of both case definitions (with some slight adaptations) and other
160 combinations, using the actual features that had been captured during our field study.

161

162

163

164 *Statistical analysis*

165 Descriptive statistics, using medians and interquartile ranges for continuous variables and
166 percentages for categorical variables, were used to summarize the results of the household
167 investigations. Comparisons were calculated by Pearson's chi-squared or Fisher exact test for
168 categorical variables and the Kruskal Wallis test for continuous variables. Differences were
169 considered statistically significant if $p < 0.05$. Diagnostic value and performance of
170 signs/symptoms and different case definitions were expressed in sensitivity, specificity, positive
171 and negative predictive value (PPV and NPV), and positive and negative likelihood ratios (LR +
172 and LR-), using standard formulas. All statistical analyses were performed using Stata 15.0
173 software (StataCorp LP, College Station, TX, USA).

174

175 *Predictive model*

176 We fit a model to predict PCR-confirmed cases using patient sex and age group, prior smallpox
177 vaccination history, and presence of signs/symptoms. We generated interaction variables for
178 every binary combination of variables, dropping interactions that were fully determined by other
179 variables. We then fit a Bayesian logistic model to random training subset of 75% of PCR-
180 confirmed cases, using a regularizing prior (Student's t) on variable coefficient to optimize for
181 out-of-sample prediction. We calculated the posterior odds ratios associated with each variable
182 and interaction, and measured out-of-sample performance on the remaining 25% of cases.
183 Model-fitting was performed in R 4.2.0 (RCoreTeam, 2022) , using the Stan modeling
184 framework (StanDevelopmentTeam, 2022) and brms package (Bürkner, 2017).

185

186 **Data Availability Statement:** De-identified data and R code for the predictive model are
187 deposited on Zenodo at <https://dx.doi.org/10.5281/zenodo.6574450> (Mande et al. 2022).

188

189 **Results**

190 Generalized skin eruption with fever evocative of human monkeypox was notified in 143
191 households, making a total of 948 people (median number of members/household: 6;
192 interquartile range [IQR] 4-9) and reported by the RECO to the local health staff. These
193 households were visited by the study teams between September 2017 and May 2019 (94 in the
194 first year and 49 in the second year of the project). In a total of 106 households (106/143;
195 74.1%), representing 678 household members, the study team confirmed that at least one case
196 responded to the study definition of suspected MPX. Overall, 138 patients (of whom 74 or, 54%,
197 were aged <15 years) fulfilled the study definition of suspect monkeypox case (Table 2).

198 The cases resided in 32 villages distributed in 12 health areas within three health zones (Aketi,
199 Buta, Titule). Eighty-nine households (89/106; 84.0%) had one suspect case, 10 had two, four
200 had three, one had four, and within two families, all members (6 and 7, respectively) had an
201 active generalized vesicular-pustular rash fitting the study definition at the time of the household
202 visit. During site visits, among households with active cases of skin eruption, 23/100 (n=100,
203 info missing for 6 households) also reported recent and distant past episodes of fever with
204 generalized skin eruption in their households (distant, i.e., >3 months earlier for 13; recent, i.e.,
205 within the last 3 months for 10).

206 Complete PCR results were obtained for 77 out of the 138 active suspect monkeypox cases
207 (55.8%). Twenty-one of 77 patients (27.3%) tested positive for MPXV, and 45, out of the 56
208 MPXV-negatives, were positive for VZV. The remaining 11 cases remained negative for both

209 MPXV and VZV. One suspect monkeypox case, negative for MPXV, was not tested for VZV.
210 Next, we compared the socio-demographic, clinical characteristics, and risk factors between the
211 21 confirmed monkeypox cases, the 45 confirmed chickenpox cases, and the 11 cases reported as
212 negative for both PCR assays (Table 3).
213 Sociodemographic characteristics (age, gender) were similar in the three groups. In terms of
214 clinical signs and symptoms, rash characteristics were the only symptoms that differed
215 significantly between monkeypox and chickenpox cases. Monkeypox confirmed cases more
216 often presented with cutaneous lesions in the same stage of the skin eruption (monomorphic)
217 (85.7% vs 40.0% for the chickenpox cases; $p=0.001$); and more often had lesions on hands palms
218 (85.7% vs 33.3%; $p<0.001$) and feet soles (71.4% vs 17.8%; $p<0.001$) compared to chickenpox
219 patients. Forty percent of both confirmed monkeypox and chickenpox patients presented with
220 ocular lesions/corneal opacities. Similarly, the frequency of cervical/submandibular
221 lymphadenopathy was not significantly different between the two groups.
222 Contact with a person with generalized skin eruption within the past 3 weeks was reported in
223 70% of the cases of all three groups with no statistical difference. The presence of another
224 suspect monkeypox case (according to the study definition) in the household tended to be more
225 frequent in confirmed chickenpox cases than in MPX cases. Recent bushmeat consumption
226 (giant pouched rat, primates, squirrels,...) was very common (>80%) in all three groups, with no
227 statistical difference.
228 A similar number of confirmed monkeypox patients was reported from the three health areas
229 (Area 1: 3/20, Area 2: 5/20, Area 3: 6/14) surveyed within the Aketi health zone. Of note, in one
230 study household, MPXV- and VZV-positive cases were found concomitantly. Of note, in the 7-
231 member household of which each individual presented with a rash, two persons were sampled,

232 and one tested positive for MPX and the other patient tested positive for VZV. For the child,
233 concurrent infection with MPX and VZV was not excluded. When comparing the clinical and
234 socio-demographic features of suspect monkeypox cases with and without molecular results
235 (Supplementary Table 1), no difference was observed except for the duration of fever (7 days
236 [IQR 3-10] versus 9 days [6-12], respectively; $p=0.008$).

237 Based on the PCR results, the case definition used in this study led to a false positive rate of 73%
238 (56 out of 77 tested samples were not confirmed as monkeypox). As detailed in Table 4, the case
239 definition for “health facility” of the DRC national program would have decreased the false
240 positive rate to 20% (corresponding to a specificity of 80%) but would have missed one-third of
241 the true monkeypox cases (sensitivity of 67%). The proposed alternative case definition (18),
242 would have an excellent sensitivity but a very low specificity (with >95% of false positives for
243 monkeypox). All three identified discriminative features (“monomorphic rash”, “rash on palms”,
244 “rash on soles”) had a weak confirming power for monkeypox ($LR+ <3$) when taken separately.
245 Only the presence of all three features together has a good predictive value ($LR+ >3$), slightly
246 better than that of the “health facility” case definition, increasing the probability of confirmed
247 monkeypox above 50% (from a baseline frequency of 27% in suspect cases). In contrast, the
248 absence of all three discriminative features would virtually exclude the diagnosis of monkeypox.

249 The predictive model (Figure 2). had 97% specificity and 80% sensitivity in predicting PCR-
250 confirmed monkeypox for in-sample cases, but only 80% specificity and 33% sensitivity for out-
251 of-sample cases. Only one feature – the interaction of “rash on palms” in male patients” was a
252 consistent predictor in >95% of model posterior samples. Other features that were positive
253 predictors in >80% of posterior samples were all interactions including “rash on palms”, “rash on
254 soles” and “monomorphic rash”. Prior vaccination against smallpox confirmed by presence of

255 vaccinia vaccine scar was the strongest predictor against PCR-confirmed monkeypox (in 93% of
256 samples).

257

258 **Discussion**

259 The enhanced surveillance of monkeypox in Bas-Uélé province by a dedicated “One Health”
260 team confirmed that only 27% of suspect cases, as identified by an adapted “community” case
261 definition, were confirmed as monkeypox. Most cases were finally diagnosed as chickenpox.

262 The investigation did not identify clear epidemiological risk factors for monkeypox. Only three
263 clinical features (monomorphic rash, rash on palms of hands, and rash on soles of feet) had some
264 discriminative value for monkeypox, but no combination of symptoms and no alternative case
265 definitions had a strong confirming power for decisive diagnosis.

266 This study has several limitations, inherent to the project and the health system in which it was
267 embedded. First, the central objective of the project was education rather than research, with a
268 progressive improvement of generic capacities towards monkeypox surveillance and detection.

269 The clinical data collected during the project have thus evolved in terms of quality as the
270 capacity increased over time, but some differences may have persisted between examinations
271 made by medical doctors (during the field visits) and by nurses during the absence of
272 supervision. Second, the intermittent provision of standard kits led to gaps in systematic skin
273 sampling (which could be better addressed during the field visits). While we can consider that
274 the subset of patients who were sampled for the molecular workup was selected at random, some
275 bias may have occurred during these periods of higher availability. The technical difficulties
276 related to sample preservation and transportation may have impacted the quality of the DNA and
277 hence of the molecular results because laboratory staff and resources had on several occasions to

278 be redirected to the reference diagnosis of Ebola during the successive outbreaks in DRC at that
279 time. This has likely caused some false-negative results, as reflected by the clinical presentation
280 of the 11 PCR-negative patients that was quite similar to that of confirmed monkeypox cases.
281 Finally, as a result of the sequential INRB testing protocol, we cannot report the proportion of
282 monkeypox cases concomitantly infected with VZV.

283 The low specificity of the case definition for community surveillance of monkeypox implies the
284 inclusion of many false positives in both the epidemiological and clinical records scattered in
285 peripheral health structures, with some under- and over-estimation of the actual caseload. Most
286 captured cases were in fact chickenpox patients, confirming that the epidemiological
287 characterization and clinical identification of monkeypox in Bas-Uélé are also seriously blurred
288 by the co-endemicity of both conditions that share many similar and overlapping features (Jezek
289 et al., 1988, Leung et al., 2019, MacNeil et al., 2009). It is expected that cases first captured by
290 the very sensitive “community” case definition are assessed through the more restrictive “health
291 facility” case definition, but this two-step clinical strategy may be not very well apprehended by
292 less trained health workers. In addition, the latter case definition still includes a substantial
293 number of non-monkeypox cases while it may create difficulties to classify the subgroup
294 captured by the “community” definition which is secondarily rejected. Based on our limited
295 dataset, we confirmed the discriminative value of some features such as the monomorphic aspect
296 of the rash (all body lesions presenting at the same stage) and the preferential localization on
297 palms and soles but also highlighted that their confirming power for monkeypox is limited. In
298 contrast with others, we did not observe any predictive value for other characteristics such as
299 cervical lymphadenopathy, ocular opacities, presence of other suspect cases in households -
300 indicative of chickenpox in our dataset - or consumption of bushmeat, since they were all

301 frequently reported in monkeypox and chickenpox confirmed patients. The negative correlation
302 with prior vaccination against smallpox further supports high residual protection against
303 monkeypox clinical diseases outcome, which is also supported by the generational divide in
304 susceptibility since smallpox vaccination was discontinued (Rimoin et al., 2010). Looking for
305 alternative case definitions, based on novel combinations of symptoms, did not substantially
306 improve the diagnostic performance. Our predictive model also highlighted the importance of a
307 monomorphic rash and localization on palms and soles. However, the model's low predictive
308 power, given its inclusion of all combinations of symptoms, shows the fundamental limitation on
309 diagnosis without point-of-care tests. Because of its epidemic potential and substantial mortality
310 and morbidity, accurate and swift diagnosis of monkeypox is crucial. There is a pressing need for
311 peripheral laboratories with easy-to-use molecular diagnostic devices (Li et al., 2017) or the
312 further provision and development of rapid point-of-care diagnostic tests such as ABICAP (Stern
313 et al., 2016), suited to the remote harsh environments where monkeypox may break out at any
314 moment.

315 Moreover, MPX antiviral treatment trials also should be conducted in Africa. For example, with
316 the antiviral tecovirimat which received approval by both FDA and EMA for the treatment of
317 MPX based on animal experiments (Grosenbach et al., 2018, Laudisoit et al., 2018). In addition,
318 the efficacy of third generation smallpox vaccines in preventing MPX is being studied in the
319 DRC. A smallpox-monkeypox vaccine has recently been validated by the FDA based on positive
320 trials in other parts of DRC (Petersen et al., 2019).

321 In conclusion, this field investigation confirmed the difficulty observed elsewhere for health and
322 community workers to clinically distinguish between monkeypox and chickenpox, two
323 conditions that with similar symptoms but have increasingly divergent management. Combining

324 lesion distribution and number, size, shape, and rugosity of lesions could potentially improve
325 field discrimination between the two diseases. Development and field evaluation of breakthrough
326 diagnostics and encouraging “One Health” intervention teams are key to timely and adequately
327 address the variety and complexity of epidemic-prone diseases such as monkeypox, especially in
328 areas with increasing evidence of co-circulation of zoonotic and anthroponotic pathogens (Bunge
329 et al., 2022). The current outbreak of monkeypox outside Africa illustrates also the importance of
330 intensified monkeypox surveillance in Africa among human and animal populations.

331

332 **Supplementary Material:** The following supporting information can be downloaded at: Table
333 S1: Comparison of sociodemographic and clinical characteristics of enrolled suspect monkeypox
334 cases with versus without molecular results.

335

336 **Acknowledgments:** The authors are grateful to the Bas-Uélé province authorities and in
337 particular the Ministry of Health of Bas-Uélé province for administrative and logistical support.
338 The researchers thank the main nurses of the visited health areas (Lizombe René and Egula
339 Franck) and the biologists of the University of Kisangani (UNIKIS) and the Centre for
340 Biodiversity Monitoring [Centre de Surveillance de la Biodiversité] for their help and scientific
341 support during field surveys (Baelo Pascal, Malekani André, Musaba Prescott, Nebese Casimir,
342 and Ngoy Steve), and National Institute of Biomedical Research (INRB) team in Kinshasa (Jean-
343 Jacques Muyembe, Elisabeth Putuka and Steve Ahuka) for their scientific support. The authors
344 are grateful to John Feigelson (Ecohealth Alliance) for producing the graphical abstract.

345

346 **Author Contributions:** Conceptualization, Robert Colebunders, Erik Verheyen, Herwig Leirs
347 and Anne Laudisoit; Data curation, Gaspard Mande, Anja De Weggheleire and Anne Laudisoit;
348 Formal analysis, Anja De Weggheleire and Noam Ross; Funding acquisition, Robert
349 Colebunders, Erik Verheyen, Herwig Leirs and Anne Laudisoit; Investigation, Gaspard Mande,
350 Innocent Akonda, Emmanuel Bottieau, Guy-Crispin Gembu, Erik Verheyen and Anne Laudisoit;
351 Methodology, Anja De Weggheleire, Emmanuel Bottieau, Anne Laudisoit and Noam Ross;
352 Project administration, Robert Colebunders, Erik Verheyen and Anne Laudisoit; Supervision,
353 Anja De Weggheleire, Emmanuel Bottieau, Erik Verheyen and Anne Laudisoit; Visualization,
354 Anne Laudisoit and Noam Ross; Writing – original draft, Gaspard Mande, Innocent Akonda,
355 Anja De Weggheleire and Emmanuel Bottieau; Writing – review & editing, All authors. All
356 authors have read and agreed to the published version of the manuscript.

357

358 **Conflicts of Interest:** The authors declare no conflict of interest.

359 **Funding:** This research was funded by the Flemish Interuniversity Council for University

360 Development Cooperation (VLIR-UOS) through the VLIR TEAM SI project

361 CD2017SIN199A102 "Strengthening the academic capacity to respond to Monkeypox

362 Outbreaks: Discrimination and Origin of Eruptive Fevers in the Democratic Republic of Congo

363 (DRC) (2017-2019)". ADW, EB, and LL were members of the Institute of Tropical Medicine's

364 Outbreak Research Team which is financially supported by the Department of Economy,

365 Science, and Innovation (EWI) of the Flemish government.

366 **Institutional Review Board Statement:** The study was conducted following the Declaration of

367 Helsinki and approved by the Ethics Committee of Antwerp University Hospital, Belgium

368 (reference 18/01/012), and the Ethics Committee of the School of Public Health of the University

369 of Kinshasa (approval number ESP/CE/077/2018). In addition to the household level consent
370 signed by the household head for the home visit and data collection, individual written informed
371 consent was obtained from each participant or its guardian in case of sample collection or picture
372 capture.

373 **References**

374 Bunge EM, Hoet B, Chen L, Lienert F, Weidenthaler H, Baer LR, et al. The changing
375 epidemiology of human monkeypox-A potential threat? A systematic review. *PLoS Negl Trop*
376 *Dis* 2022;16(2):e0010141.

377 Bürkner P-C. brms: An R Package for Bayesian Multilevel Models Using Stan. *Journal of*
378 *Statistical Software* 2017;80(1).

379 Diaz JH. The Disease Ecology, Epidemiology, Clinical Manifestations, Management,
380 Prevention, and Control of Increasing Human Infections with Animal Orthopoxviruses.
381 *Wilderness Environ Med* 2021;32(4):528-36.

382 DRC. Guide Technique pour la surveillance intégrée de la maladie et riposte: SIMR. . In:
383 Direction de Lutte contre la Maladie MdlSP, République Démocratique du Congo. , editor.
384 [internet]2011.

385 DRC. Guide de prise en charge des épidémies dans une zone de santé: Monkeypox. . In:
386 Direction de Lutte contre la Maladie MdlSP, RD du Congo., editor. [internet]2012.

387 Durski KN, McCollum AM, Nakazawa Y, Petersen BW, Reynolds MG, Briand S, et al.
388 Emergence of Monkeypox - West and Central Africa, 1970-2017. *MMWR Morb Mortal Wkly*
389 *Rep* 2018;67(10):306-10.

390 Erez N, Achdout H, Milrot E, Schwartz Y, Wiener-Well Y, Paran N, et al. Diagnosis of Imported
391 Monkeypox, Israel, 2018. *Emerg Infect Dis* 2019;25(5):980-3.

392 Groesenbach DW, Honeychurch K, Rose EA, Chinsangaram J, Frimm A, Maiti B, et al. Oral
393 Tecovirimat for the Treatment of Smallpox. *N Engl J Med* 2018;379(1):44-53.

394 Hobson G, Adamson J, Adler H, Firth R, Gould S, Houlihan C, et al. Family cluster of three
395 cases of monkeypox imported from Nigeria to the United Kingdom, May 2021. *Euro Surveill*
396 2021;26(32).

397 Hoff NA, Doshi RH, Colwell B, Kebela-Illunga B, Mukadi P, Mossoko M, et al. Evolution of a
398 Disease Surveillance System: An Increase in Reporting of Human Monkeypox Disease in the
399 Democratic Republic of the Congo, 2001-2013. *Int J Trop Dis Health* 2017;25(2).

400 Hughes CM, Liu L, Davidson WB, Radford KW, Wilkins K, Monroe B, et al. A Tale of Two
401 Viruses: Coinfections of Monkeypox and Varicella Zoster Virus in the Democratic Republic of
402 Congo. *Am J Trop Med Hyg* 2020;104(2):604-11.

403 Jezek Z, Szczeniowski M, Paluku KM, Mutombo M, Grab B. Human monkeypox: confusion
404 with chickenpox. *Acta Trop* 1988;45(4):297-307.

405 Ladnyj ID, Ziegler P, Kima E. A human infection caused by monkeypox virus in Basankusu
406 Territory, Democratic Republic of the Congo. *Bull World Health Organ* 1972;46(5):593-7.

407 Laudisoit A. Reinforcing academic capacities to Monkeypox outbreaks response: Diagnostic
408 and origin of eruptive fevers in the Democratic Republic of the Congo (DRC) 2017. Available
409 from: [https://www.researchgate.net/project/Reinforcing-academic-capacities-to-Monkeypox-](https://www.researchgate.net/project/Reinforcing-academic-capacities-to-Monkeypox-outbreaks-reponse-Diagnostic-and-origin-of-eruptive-fevers-in-the-Democratic-Republic-of-the-Congo-DRC)
410 [outbreaks-reponse-Diagnostic-and-origin-of-eruptive-fevers-in-the-Democratic-Republic-of-the-](https://www.researchgate.net/project/Reinforcing-academic-capacities-to-Monkeypox-outbreaks-reponse-Diagnostic-and-origin-of-eruptive-fevers-in-the-Democratic-Republic-of-the-Congo-DRC)
411 [Congo-DRC](https://www.researchgate.net/project/Reinforcing-academic-capacities-to-Monkeypox-outbreaks-reponse-Diagnostic-and-origin-of-eruptive-fevers-in-the-Democratic-Republic-of-the-Congo-DRC).

412 Laudisoit A, Tepage F, Colebunders R. Oral Tecovirimat for the Treatment of Smallpox. *N Engl*
413 *J Med* 2018;379(21):2084-5.

414 Laudisoit A, VE, Baelo P., Akonda I., Nebesse C., Ngoy S., Gembu G., Tepage F., Muyembe
415 J.J., Alworonga O., Mande D., Angotolwa Z., Leirs H., Ngbonda D., Colebunders R. A One
416 Health team to improve Monkeypox virus outbreak response: An example from the Democratic
417 Republic of the Congo. ECTMIH. Antwerpen2017.

418 Leung J, McCollum AM, Radford K, Hughes C, Lopez AS, Guagliardo SAJ, et al. Varicella in
419 Tshuapa Province, Democratic Republic of Congo, 2009-2014. Trop Med Int Health
420 2019;24(7):839-48.

421 Li D, Wilkins K, McCollum AM, Osadebe L, Kabamba J, Nguete B, et al. Evaluation of the
422 GeneXpert for Human Monkeypox Diagnosis. Am J Trop Med Hyg 2017;96(2):405-10.

423 MacNeil A, Reynolds MG, Carroll DS, Karem K, Braden Z, Lash R, et al. Monkeypox or
424 varicella? Lessons from a rash outbreak investigation in the Republic of the Congo. Am J Trop
425 Med Hyg 2009;80(4):503-7.

426 Makhani L, Khatib A, Corbeil A, Kariyawasam R, Raheel H, Clarke S, et al. 2018 in review: five
427 hot topics in tropical medicine. Trop Dis Travel Med Vaccines 2019;5:5.

428 Mauldin MR, McCollum AM, Nakazawa YJ, Mandra A, Whitehouse ER, Davidson W, et al.
429 Exportation of Monkeypox Virus From the African Continent. The Journal of Infectious
430 Diseases 2020;225(8):1367-76.

431 Osadebe L, Hughes CM, Shongo Lushima R, Kabamba J, Nguete B, Malekani J, et al.
432 Enhancing case definitions for surveillance of human monkeypox in the Democratic Republic of
433 Congo. PLoS Negl Trop Dis 2017;11(9):e0005857.

434 Petersen BW, Kabamba J, McCollum AM, Lushima RS, Wemakoy EO, Muyembe Tamfum JJ,
435 et al. Vaccinating against monkeypox in the Democratic Republic of the Congo. Antiviral Res
436 2019;162:171-7.

437 Rao AK, Schulte J, Chen TH, Hughes CM, Davidson W, Neff JM, et al. Monkeypox in a
438 Traveler Returning from Nigeria - Dallas, Texas, July 2021. *MMWR Morb Mortal Wkly Rep*
439 2022;71(14):509-16.

440 RCoreTeam. R: A language and environment for statistical computing. ; 2022. Available from:
441 <https://www.R-project.org/>.

442 Rimoin AW, Mulembakani PM, Johnston SC, Smith JOL, Kisalu NK, Kinkela TL, et al. Major
443 increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in
444 the Democratic Republic of Congo. *Proceedings of the National Academy of Sciences*
445 2010;107(37):16262-7.

446 Sklenovská N, Van Ranst M. Emergence of Monkeypox as the Most Important Orthopoxvirus
447 Infection in Humans. *Front Public Health* 2018;6:241-.

448 StanDevelopmentTeam. Stan Modeling Language Users Guide and Reference Manual, 2.29;
449 2022. Available from: <https://mc-stan.org>.

450 Stern D, Olson VA, Smith SK, Pietraszczyk M, Miller L, Miethe P, et al. Rapid and sensitive
451 point-of-care detection of Orthopoxviruses by ABICAP immunofiltration. *Virology*
452 2016;13(1):207.

453 WHO. Disease Outbreak News; Multi-country monkeypox outbreak in non-endemic countries.;
454 2022. Available from: [https://www.who.int/emergencies/disease-outbreak-news/item/2022-](https://www.who.int/emergencies/disease-outbreak-news/item/2022-DON385)
455 [DON385](https://www.who.int/emergencies/disease-outbreak-news/item/2022-DON385). [Accessed 23/05/2022].

456 Yong SEF, Ng OT, Ho ZJM, Mak TM, Marimuthu K, Vasoo S, et al. Imported Monkeypox,
457 Singapore. *Emerg Infect Dis* 2020;26(8):1826-30.

458

459

Table 1. Clinical case definitions for monkeypox applied in the Democratic Republic of the Congo surveillance system and in this study.

| | |
|---|--|
| DRC clinical case definition for use in health facilities (clinical case definition A in Osadebe et al., 2017) | Any person presenting with sudden onset of high fever followed after a few days by a vesicular-pustular rash predominantly on the face, palms of the hands, and soles of the feet, or presence of at least 5 variola-like scars. |
| DRC clinical case definition for community surveillance | Any person presenting with fever and a cutaneous rash |
| Clinical case definition as applied in our study | Any person with an active generalized vesicular-pustular rash (i.e. presenting at least five cutaneous lesions such as macules, papules, vesicles, pustules, or crusts) |
| Clinical case definition B (as evaluated in Osadebe et al., 2017) | Any person with a rash with deep-seated/firm lesions AND either febrile prodrome or lymphadenopathy or lesion of palms or soles |

Table 2. Overview of enhanced surveillance results from September 2017 to May 2019

| Health zones | Health areas | Nr individuals /households visited | | Suspect cases (households with a suspect case) | | Suspect cases (households) sampled and with test result | | Suspect cases (households) with PCR-MPX positive result | | Suspect cases (households) with PCR-VZV positive result* | |
|--------------|--------------|------------------------------------|------------|--|------------|---|-------------|---|-------------|--|-------------|
| | | Individuals | Households | Nr | % | Nr | % | Nr | % | Nr | % |
| | | Aketi | 1 | 446 | 59 | 30 (22) | 6.7 (37.3) | 22 (17) | 73.3 (77.3) | 13.6 (3) | 13.6 (17.6) |
| | 2 | 195 | 35 | 53 (35) | 27.2 (100) | 23 (20) | 43.4 (57.1) | 15 (5) | 65.2 (25) | 15 (13) | 65.2 (65.0) |
| | 3 | 183 | 33 | 38 (33) | 20.8 (100) | 20 (18) | 52.5 (54.5) | 30.0 (6) | 30.0 (33.3) | 8 (7) | 40.0 (38.9) |
| | 4 | 6 | 1 | 1 (1) | 16.7 (100) | 1 (1) | 100 (100) | 1 (1) | 100 (100) | 0 (0) | 0.0 (0.0) |
| | 5 | 5 | 1 | 1 (1) | 20.0 (100) | 1 (1) | 100 (100) | 0 (0) | 0.0 (0.0) | 0 (0) | 0.0 (0.0) |
| | 6 | 1 | 1 | 1 (1) | 100 (100) | 1 (1) | 100 (100) | 0 (0) | 0.0 (0.0) | 1 (1) | 100 (100) |

| | | | | | | | | | | | | |
|--------------|------------------|------------|--------------|-----------------|-------------------|--------------|----------------|---------------|----------------|---------------|----------------|---------------|
| | | | | 14.8 | 68 | 47.8 | 15 | 18.0 | 41 | 81.8 | | |
| | Sub-total | 836 | 130 | 124 (93) | (71.5) | (58) | (59.1) | (15) | (23.1) | (33) | (80.8) | |
| Buta | 7 | 32 | 4 | 4 (4) | 12.5 (100) | 4 (4) | 100 (100) | 3 (3) | 75.0 (75.0) | 1 (1) | 25.0 (25.0) | |
| | 8 | 24 | 2 | 2 (2) | 8.3 (100) | 1 (1) | 50.0 (50.0) | 0 (0) | 0.0 (0.0) | 1 (1) | 100 (100) | |
| | 9 | 20 | 2 | 2 (2) | 10.0 (100) | 1 (1) | 50.0 | 1 (1) | 100 (100) | 0 (0) | 0.0 (0.0) | |
| | 10 | 10 | 1 | 1 (1) | 10.0 (100) | 0 (0) | 0.0 (0.0) | 0 (0) | 0.0 (0.0) | 0 (0) | 0.0 (0.0) | |
| | 11 | 10 | 2 | 2 (2) | 20.0 (100) | 2 (2) | 100 (100) | 0 (0) | 0.0 (0.0) | 2 (2) | 100 (100) | |
| | Sub-total | 96 | 11 | 11 (11) | 11.5 (100) | 8 (8) | (72.7) | 4 (4) | (50.0) | 4 (4) | (50.0) | |
| Titule | 12 | 16 | 2 | 3 (2) | 18.7 (100) | 2 (2) | 50.0 (50.2) | 2 (2) | 100 (100) | 0 (0) | 0.0 (0.0) | |
| Total | 948 | 143 | (106) | 14.6 | (74.1) | (68) | 56.5 | (64.1) | (21) | (30.9) | (37) | (54.4) |




Figure 1: Map of the Democratic Republic of the Congo (DRC) indicating the Bas-Uélé province and the health zones of Aketi, Buta, and Titule (study area).

Table 3. Socio-demographics, clinical characteristics, and risk factors for the confirmed monkeypox (MPXV positive), chickenpox (VZV positive), and PCR negative cases * MPX and VZV case in the same household of 7 members, all presenting as clinical suspects. Note: rash on the face is not reported here as it was part of the study definition (frequency 100% in all three groups).

| | MPX positive (n=21) | VZV positive (n=45) | MPX and VZV negative (n=11) | p- value |
|--------------------------|------------------------------------|------------------------------------|--|---------------------|
| - | | | | |
| Age (median, IQR) | 16 (4-30) | 18 (7-29) | 11 (5-27) | 0.60 |
| Age groups (n,%) | | | | |
| <5 years | 6/21 (28.6) | 6/45 (13.3) | 2/11 (18.2) | 0.46 |
| | | 13/45 | 5/11 (45.4) | |
| 5-15 years | 4/21 (19.1) | (28.9) | | |
| | | 11/45 | 0 (0.0) | |
| 15-25 years | 4/21 (19.1) | (24.4) | | |
| | | 12/45 | 4 (36.4) | |
| 25-40 years | 5/21 (23.8) | (26.7) | | |
| >40 years | 2/21 (9.5) | 3/45 (6.7) | 0 (0.0) | |
| Gender (n, %) | | | | |
| Male | 14/21 (66.7) | 25/45 (55.6) | 6/11 (54.6) | 0.72 |
| Female | 7/21 (33.3) | 20/45 | 5/11 (45.4) | |

| | | | | |
|---|--------------|--------------|-------------|------------------|
| | | (44.4) | | |
| Past episode of generalized rash (n,%) | 0/21 (0.0) | 2/45 (4.4) | 0/11 (0.0) | 1.00 |
| Days since start current episode of rash (median, IQR) | 7 (6-12) | 5 (3-6) | 7 (6-10) | 0.001 |
| Fever prodrome (n,%) | 20/21 (95.2) | 42/45 (93.3) | 11/11 (100) | 1.00 |
| Days since start of fever (median, IQR) | 8 (2-10) | 6 (2-9) | 9 (8-12) | 0.03 |
| Rash presentation (n, %) | | | | |
| Lesions of same stage (monomorphic) | 18/21 (85.7) | 18/45 (40.0) | 7/11 (63.6) | 0.001 |
| Lesions of several different stages | 3/21 (14.3) | 27/45 (60.0) | 4/11 (36.4) | |
| Rash on hand palms (n, %) | 18/21 (85.7) | 15/45 (33.3) | 8/11 (72.7) | <0.001 |
| Rash on foot soles (n, %) | 15/21 (71.4) | 8/45 (17.8) | 9/11 (81.8) | <0.001 |
| Lymphadenopathy (submandibular & cervical) (n,%) | 10/21 (47.6) | 15/45 (33.3) | 4/11 (36.4) | 0.54 |
| Ocular lesions/corneal opacities (%) | | | | |
| None | 13/21 (61.9) | 28/45 (62.2) | 9/11 (81.8) | 0.72 |
| Unilateral | 2/21 (9.5) | 2/45 (4.4) | 0/11 (0.0) | |
| Bilateral | 6/21 (28.6) | 15/45 | 2/11 (18.2) | |

| | | | | |
|---|------------------------------|------------------------------|-----------------|-------------|
| | | (33.3) | | |
| Contact with any person with a generalized rash in the last 3 weeks (n, %) | 12/18 (66.7) | 24/34 (70.6) | 8/9 (88.9) | 0.57 |
| Days since contact (median, IQR) | 14 (11-16) | 12 (9-14) | 11 (11-18) | 0.36 |
| Other suspect monkeypox cases in the household at home visit (n, %) | | | | 0.04 |
| | 19/21 (90.5) | 26/45 (57.8) | 10/11 (90.9) | |
| 0 | | 11/45 (24.4) | 1/11 (9.1) | |
| 1 | 1/21 (4.8) | | | |
| 2 | 0/21 (0.0) | 7/45 (15.6) | 0/11 (0.0) | |
| 6 | 1/21 (4.8)* | 1/45 (2.2)* | 0/11 (0.0) | |
| Consumption of bushmeat in the last 3 weeks (n, %) | 19/21 (90.5) [†] | 35/45 (77.8) [†] | 7/11 (63.6) | 0.21 |
| Type bushmeat eaten (n, %) | | | | |
| “Bandro” or “Motomba” (Gambian rat, <i>Cricetomys gambianus</i>) | 6/19 (31.6) | 19/35 (54.3) | 1/7 (14.3) | |
| “Apwa” or “Makako” or “Likako” (Monkey, <i>Pan troglodytes</i>) | 5/19 (26.3) | 5/35 (14.3) | 2/7 (28.6) | |
| "Esende" (squirrel, <i>Funisciurus</i>) | 3/19 (15.8) | 5/35 (14.3) | 3/7 (42.8) | |
| "Kulupa" | 3/19 (15.8) | 4/35 (11.4) | 0/7 (0.0) | |
| “Mboloko” (Duiker, <i>Philanthomba</i>) | 2/19 (10.5) | 2/35 (5.7) | 0/7 (0.0) | |

| | | | | | |
|---|----------|-------------|------------|------------|------|
| | “Moputé” | 0/19 (0.0) | 0/35 (0.0) | 1/7 (14.3) | |
| Days since last bushmeat (median, IQR) | | 10.5 (7-14) | 10 (9-14) | 12 (7-17) | 0.94 |

* MPX and VZV case in the same household of 7 members, all presenting as clinical suspects.

Note: rash on the face is not reported here as it was part of the study definition (frequency 100% in all three groups)

† Calculated considering missing answers as ‘not having consumed bushmeat during the last 3 weeks’

† Calculated considering missing answers as ‘not having consumed bushmeat during the last 3 weeks’.

Table 4. Diagnostic performance of “health facility” and alternative case definitions in the study dataset

| | True positive (n) | False positive (n) | True negatives (n) | False negatives (n) | Sensitivity (%) | Specificity (%) | Positive Predictive Value (PPV) | Negative Predictive Value (NPV) | PPV (%)* (or probability if criteria absent) | NPV (%) | Probability if criteria absent (%) |
|--|-------------------|--------------------|--------------------|---------------------|-----------------|-----------------|---------------------------------|---------------------------------|--|---------|------------------------------------|
| DRC “health facility” case definition: (Vesicular-pustular) rash AND fever prodrome, AND lesions on hands palms and feet soles | 14 | 11 | 45 | 7 | 66.7 | 80.3 | 39 | 0 | 56.0 | 65 | 13.5 |
| Alternative case definition B (Osadebe et al., 2017) : Rash AND fever prodrome, OR rash on hands palms or feet soles, OR submandibular/cervical lymphadenopathy | 21 | 54 | 2 | 0 | 100 | 3.6 | 04 | 06 | 28.0 | 00 | 0 |
| Rash after a fever prodrome, AND monomorphic lesions | 18 | 25 | 31 | 3 | 85.7 | 55.3 | 19 | 02 | 41.9 | 91 | 8.8 |

| | | | | | | | | | | | |
|---|----|----|----|----|------|------|-----|-----|------|-----|------|
| | | | | | | | 2 | 6 | | 2 | |
| Rash after fever prodrome, AND lesions on hand palms | 18 | 23 | 33 | 3 | 85.7 | 58.9 | 2.0 | 0.2 | 43.9 | 1.7 | 8.3 |
| Rash after fever prodrome, AND lesions on feet soles | 15 | 17 | 39 | 6 | 71.4 | 69.6 | 2.3 | 0.4 | 46.9 | 6.7 | 13.3 |
| Rash after fever prodrome, AND monomorphic lesions, AND lesions on hand palms or feet soles | 16 | 16 | 40 | 5 | 76.2 | 71.4 | 2.6 | 0.3 | 50.0 | 8.9 | 11.1 |
| Rash after fever prodrome, AND monomorphic lesions, AND lesions on hand palms and feet soles | 11 | 8 | 48 | 10 | 52.4 | 85.7 | 3.6 | 0.2 | 57.9 | 2.8 | 17.2 |
| Rash after fever prodrome, AND monomorphic lesions, OR lesions on hand palms or feet soles) | 21 | 38 | 18 | 0 | 100 | 32.1 | 1.4 | 0.6 | 35.6 | 1.0 | 0 |

Note: All patients had at least 5 active lesions; LR denotes likelihood ratio; PPV positive predictive value; NPV negative predictive value.

*The pre-test probability of confirmed monkeypox was 27.3% (21/77) in suspect monkeypox cases (see study clinical case definition)

Note: All patients had at least 5 active lesions; LR denotes likelihood ratio; PPV positive predictive value; NPV negative predictive value *The pre-test probability of confirmed monkeypox was 27.3% (21/77) in suspect monkeypox cases (see study clinical case definition)




Figure 2. Coefficients for all variables and interactions (features) in the predictive model, scaled as odds ratios (OR). Mean OR is printed in the parentheses of each feature, with mean (dots), 66% posterior interval (thick lines), 95% posterior interval (thin lines), and full posterior shape (density plots) shown in the plot.